Massive Bio, an AI-powered clinical trial matching platform, and Foundation Medicine have announced a strategic partnership to expand patient access to advanced clinical trials. The collaboration combines Massive Bio’s patient-matching technology with Foundation Medicine’s expertise in next-generation sequencing (NGS) and its network of healthcare providers to improve trial enrollment and access to cutting-edge cancer treatments.
Massive Bio and Foundation Medicine have partnered to address the low enrollment rates in oncology clinical trials, with only 8% of eligible patients participating. As rare cancer treatments grow, about 80% of global clinical studies fail to meet enrollment goals, according to a 2020 report. This collaboration combines Massive Bio’s AI-driven patient-matching technology and Foundation Medicine’s expertise in next-generation sequencing (NGS) to boost trial participation.
Dr. Arturo Loaiza-Bonilla, CMO at Massive Bio, highlighted how AI and data integration accelerate accurate clinical trial matching, improving patient outcomes. Massive Bio’s Synergy-AI platform analyzes medical and biomarker data to match patients with over 16,000 trials, optimizing trial enrollment and reducing screening failures.
The partnership aims to expand clinical trial access by leveraging both companies’ networks, AI techniques, and digital health platforms. Heather Jorajuria, Senior VP at Foundation Medicine, emphasized their focus on personalized treatment options, including clinical trials, to support patient care decisions.
Massive Bio, founded in 2015, transforms the pharmaceutical value chain by improving drug development and commercialization through AI-enabled real-world data. With a global presence and recognition from initiatives like the Cancer Moonshot, Massive Bio is committed to increasing equitable access to clinical trials and data-driven cancer treatment.
